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Abstract
Background: HIV-1 transcription initiation depends on cellular transcription factors that bind to promoter
sequences in the Long Terminal Repeat (LTR). Each HIV-1 subtype has a specific LTR promoter configuration and
even minor sequence changes in the transcription factor binding sites (TFBS) or their arrangement can impact
transcriptional activity. Most latency studies have focused on HIV-1 subtype B strains, and the degree to which LTR
promoter variation contributes to differences in proviral latency is therefore largely unknown. Latency differences
may influence establishment and size of viral reservoirs as well as the possibility to clear the virus by therapeutic
intervention.
Results: We investigated the proviral transcriptional latency properties of different HIV-1 subtypes as their LTRs
have unique assemblies of transcription factor binding sites. We constructed recombinant viral genomes with the
subtype-specific promoters inserted in the common backbone of the subtype B LAI isolate. The recombinant
viruses are isogenic, except for the core promoter region that encodes all major TFBS, including NFB and Sp1
sites. We developed and optimized an assay to investigate HIV-1 proviral latency in T cell lines. Our data show that
the majority of HIV-1 infected T cells only start viral gene expression after TNFa activation.
Conclusions: There were no gross differences among the subtypes, both in the initial latency level and the activation
response, except for subtype AE that combines an increased level of basal transcription with a reduced TNFa response.
This subtype AE property is related to the presence of a GABP instead of NFB binding site in the LTR.
Background
Combined antiretroviral therapy (cART) is able to sup-
press the HIV-1 plasma RNA load in patients to undetect-
able levels. Unfortunately, the treatment does not lead to a
complete eradication of the virus from the infected indivi-
dual. Even after many years of successful cART, the virus
rebounds from latently integrated proviral DNA reservoirs
and re-establishes systemic infection upon interruption of
therapy [1-4]. HIV-1 proviral latency may be an effective
means to evade the immune system, since the infected cell
will go unnoticed by the immune system as long as viral
antigens are not expressed and presented. The pool of
latent proviruses is established early during infection and
forms a steady source of proviral DNA that can last a life-
time for infected individuals [5-7]. The majority of the
latent proviruses reside in long-lived memory CD4+
T cells, but other cellular reservoirs, such as monocytes,
macrophages and dendritic cells, can also harbor latent
proviruses [8-11]. HIV-1 latency remains a formidable bar-
rier towards virus eradication as therapeutic attempts to
purge these reservoirs have been unsuccessful [3,9,12,13].
Previously reported contributors to proviral latency
include suppressive effects of cellular microRNAs, an
impaired viral Tat-TAR axis, and epigenetic silencing
via histone modification and DNA hypermethylation
[14-18]. Most of these modulators have been studied in
artificial cell line models for HIV-1 latency, but some of
these mechanisms were found to be operational in rest-
ing CD4+ T-cells from HIV infected patients [19,20].
HIV-1 transcriptional activation from latency depends
on cellular transcription factors that bind to the Long
Terminal Repeat (LTR) promoter. Differences in promo-
ter activity among the HIV-1 subtypes have been
reported, consistent with the fact that their LTRs have
specific configurations of transcription factor-binding
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sites (TFBS), including variation in the number and
sequence of NFB, STAT5 and C/EBP sites [21-25].
Such subtype-specific promoter characteristics correlate
with significant differences in terms of viral replication
kinetics and the response to environmental changes
[26]. The interaction between cell type specific tran-
scription factors and LTR sites is crucial for the regula-
tion of virus expression and possibly proviral latency.
Therefore, we investigated the influence of the subtype-
specific promoters on HIV-1 transcriptional latency in a
single round infection-based latency assay model.
We demonstrate that the majority of the HIV-1
infected T cells initiate viral production only after TNFa
activation. There were no gross differences in latency and
activation properties among the subtypes, except for sub-
type AE. This subtype combines increased levels of pro-
ductive infection with a reduced TNFa response, which
correlates nicely with the presence of a GABP instead of
an NFB transcription factor binding site in its LTR.
Results
Latency model
We have previously described a single round infection
assay to determine HIV-1 transcriptional latency, which
occurs even in actively dividing T cells [27]. In this assay
the SupT1 T cell line is infected with HIV-1LAI for
4 hours after which the fusion inhibitor T1249 is added
to prevent new infections (Figure 1A). The culture is split
24 hours post infection and either treated with anti-
latency drugs or not (mock). Treated cells are harvested
24 hours later, fixed, stained for intracellular CA-p24 and
analyzed by FACS. The living cell population was subse-
quently scored for intracellular CA-p24 production
(Figure 1B).
First, we optimized the latency assay to score the
impact of cellular stimuli on the HIV-1 subtype B strain
LAI and tested the cytokine TNFa as anti-latency drug.
The subtype B LTR promoter contains two NFB bind-
ing sites through which transcription can be triggered by
activation of the NFB pathway with TNFa [28-32]. In
addition, NFB stimulates transcriptional elongation by
RNA Polymerase II through binding of the pTEFb cofac-
tor [33]. We also tested Vorinostat (SAHA), an inhibitor
of histone deacetylases, which creates a more open
nucleosome conformation thereby making the HIV-1
promoter more accessible to transcription factors [34,35].
In the mock treated culture, 3.4% of the cells produced
CA-p24, which increased to 10.1% in the TNFa treated
culture (Figure 1C). The ratio between TNFa and mock
treated cultures ("fold activation”) is used as a measure of
viral latency. TNFa treatment induced a significant 3-
fold increase in the percentage of CA-p24 positive cells
(Figure 1D). In this assay, we only scored the produc-
tively infected cells, either directly or after drug
treatment. We did not detect unresponsive or defective
proviral genomes. The results indicated that there are at
least 3 times as many latent integration events compared
to productive integrations of an intact provirus in SupT1
T cells that can be activated upon TNFa treatment. Vori-
nostat has a less pronounced effect as CA-p24 positivity
is increased from 3.4% to 4.8%, yielding a 1.5-fold activa-
tion. Combinations of both anti-latency drugs did not
yield any further significant increases in activation over
the TNFa effect (results not shown). In this setting of
recently integrated proviruses, Vorinostat has no addi-
tional effect over the already strong effect of TNFa.
These results do not necessarily mean that all latently
integrated proviruses are activated. It is likely that we
cannot activate all latently integrated proviruses. Even
latency studies using (clonal) cell lines, with each indivi-
dual cell containing a latently integrated provirus, cannot
purge 100% of the proviruses out of latency using a mix-
ture of anti-latency drugs [18,27,28,36-40].
TNFa stimulation affects the process of HIV-1 tran-
scription, but might also affect the amount of proviruses
generated upon cell stimulation. To exclude an effect of
TNFa induction on the efficiency of reverse transcription
and provirus formation, we performed a real-time Taq-
Man assay to score the average number of HIV-1 DNA
copies per cell. We measured no difference between
TNFa induced and mock treated after 24 hours of stimu-
lation (data not shown), demonstrating that TNFa does
not influence the efficiency of reverse transcription and/
or the amount of viral DNA that is produced, consistent
with an exclusive impact on LTR-mediated transcription.
Linear range of the latency model
To investigate the linear range of this latency assay, we
infected SupT1 cells with increasing amounts of subtype
B and determined the percentage of CA-p24 positive
cells with and without TNFa activation. Upon increasing
the virus input, more cells become infected and TNFa
activation yielded an increase in the percentage of CA-
p24 positive cells (Figure 2A). The fold activation, how-
ever, gradually decreased with increasing viral input
(Figure 2B). A possible explanation for this is that at high
viral input cells become infected by multiple viruses, with
transcriptionally active proviruses ‘overruling’ silent
copies. Such cells will be quantified as CA-p24 positive,
leading to an underestimation of latent proviruses. At the
other end of the spectrum, results became more variable
and thus less reliable when less than 1% CA-p24 positive
cells were scored in the non-treated control. In subse-
quent infection experiments, we have titrated the virus
such that 1 to 5% of the cells became CA-p24 positive
without activation.
The results presented thus far demonstrate that TNFa
treatment increases the number of CA-p24 producing
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cells. To determine whether cells also start producing
more CA-p24 upon TNFa stimulation, we analyzed the
mean fluorescent intensity (MFI) of the CA-p24 positive
cells. As with fold activation, we used MFI ratios of
induced to non-treated cultures to determine the rela-
tive change in intracellular CA-p24 production level.
This MFI ratio upon TNFa treatment was close to 1,
indicating that TNFa treatment does not increase the
viral gene expression levels, but only the number of
active proviruses (Figure 2C). To check whether perhaps
more CA-p24 was secreted, the concentration of CA-
p24 in the culture supernatant was quantified by ELISA.
The TNFa induced cultures showed increased CA-p24
levels in the supernatant since TNFa induced more cells
to produce CA-p24 (Figure 2D). When we correlated
the extracellular CA-p24 levels with the number of CA-
p24 producing cells, an increase was observed upon
TNFa induction in the cultures infected with 3 ng and
9 ng CA-p24 as viral input for infection. However, these
differences were not statistically significant (Figure 2E).
Figure 1 HIV-1 latency assay. A: Schematic of the HIV-1 latency assay. SupT1 T cells are infected with HIV-1 for 4 hours, free virus is washed
away, and the fusion inhibitor T1249 is added to prevent new infections. Infected cultures are split 24 hours after infection into a mock and
anti-latency drug treated culture. Cells are harvested 24 hours after treatment, stained for intracellular CA-p24 and analyzed by FACS. The fold
activation (as viral latency marker) is the ratio of CA-p24 positive cells in the drug versus mock treated sample. B: Representative FACS analysis.
Live cells are gated using the Forward/Sideward scatter (FSC/SSC) and scored for CA-p24 positivity in the RD1 channel. C: Latency assay:
percentages of CA-p24 positive cells in control (mock treated), TNFa treated, Vorinostat treated and DMSO treated (mock for Vorinostat treated)
cultures. The results presented are the average values of two independently produced virus stocks, which were both used in two independent
infections. Significant difference (*) was determined with the student T-test (Graphpad Prism). D: The fold activation (percentage CA-p24 positive
cells in drug induced culture versus mock culture).
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Thus, the latency model optimized for the wild-type
HIV-1 subtype B allows one to score for activation of
latent proviruses.
Latency over time
We were interested in monitoring proviral latency over
an extended time window. The fusion inhibitor T1249
remained present in these cultures to prevent spreading
of the input virus. A sample of the cultures was split on
day 2, 7 and 14 and either TNFa or mock treated. The
cells were harvested 24 hours later and analyzed by
FACS. The percentage of CA-p24 positive cells in the
mock culture decreased gradually over time from 3.3%
to 0.4% (Figure 3A). The TNFa-treated level of CA-p24
positive cells also decreased, but less dramatically. This
indicates that the fold activation as latency measurement
Figure 2 Performance of the HIV-1 latency assay. A: Average percentages of CA-p24 positive cells as determined by FACS in SupT1 T cells
infected with increasing concentrations of HIV-1LAI (ng/infection). Cells were either mock treated or TNFa induced. B: Fold activation from
latency with increasing viral input. C: Ratio MFI of TNFa induced versus mock cultures. D: Extracellular CA-p24 concentrations in TNFa induced
and mock treated cultures. E: The concentration of extracellular CA-p24 was corrected for the percentage of intracellular CA-p24 positive cells.
Results are shown as the ratio of extracellular versus intracellular CA-p24. The results presented are the average values that were obtained with
three independently produced virus stocks, and each stock was used for two independent infections.
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increased considerably from 3-fold on day 3 to 10-fold
on day 15 (Figure 3C). However, as described above, a
too low percentage of CA-p24 positive cells yields less
reproducible values, and we therefore decided to focus
on the latency measurement after 24 hours. Neverthe-
less, the data in Figure 3C do clearly demonstrate that
latency gets more dramatic over time.
Similar experiments were performed with the HDAC
inhibitor Vorinostat (Figure 3B and 3D). Over time,
both mock and Vorinostat treated cultures showed a
decrease in number of CA-p24 positive cells, and the
activation from latency increased from 1.5-fold on day 3
to 2.4-fold on day 15.
Latency properties of different HIV-1 subtypes and T cell
lines
To investigate the influence of the subtype-specific pro-
moter on proviral latency, SupT1 cells were infected with
an equal amount of the different viruses. Without indu-
cers, subtype B yielded 3.4% CA-p24 positive cells, which
represented the basal transcription level (Figure 4A). The
subtypes A, C, D, F and AG yielded very similar percen-
tages, but subtypes G and AE demonstrated an increase
in their basal transcription activity. Upon TNFa activa-
tion, percentages of CA-p24-producing cells increased
for all subtypes, with an activation of around 3-fold,
except for subtypes G and AE (Figure 4B). Activation of
subtype G was only 2.2-fold, and subtype AE was even
less potent at 1.5-fold. Thus, subtypes with a higher basal
transcription level were less inducible with TNFa. In
other words, subtypes AE and G proviruses were less
prone to become latent. The HDAC inhibitor Vorinostat
induced activation from latency for all subtypes, but with
a reduced potency compared to TNFa (Figure 4C). How-
ever, the same subtype trends were apparent, with the
highest activation for subtype C and the lowest induction
for subtype AE.
We already showed that subtype B exhibits a more
severe latency profile over time. The subtype-specific
cultures were also assayed over longer periods, and the
Figure 3 HIV-1 latency over time. AB: SupT1 T cells were infected with HIV-1LAI. On day 2, 7 and 14 the culture was split and either mock
treated, induced with anti-latency drugs (TNFa or Vorinostat) or passaged and cultured for another week, when the protocol was repeated. Cells
were harvested 24 hours after treatment (day 3, 8 and 15 respectively). Percentages of CA-p24 positive cells were determined by FACS. CD: The
fold activation from latency. The results presented reflect the average of two independently produced virus stocks, and each was used in two
independent infections.
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latent provirus was activated with TNFa. Subtype G,
which exhibits reduced latency compared to B, also
obtains a more dramatic latency profile over time (Addi-
tional File 1 Fig. S1A). However, subtype AE activation
from latency remains close to 1.5-fold, the same latency
value as measured at day 2 post infection. Thus, subtype
AE infection starts with higher basal transcription levels,
exhibits a reduced latency and the AE latency profile
does not become more dramatic over time as observed
for the other subtypes.
Similar experiments were performed with the HDAC
inhibitor Vorinostat. As expected, activation does not
reach similar levels as TNFa treatment (Additional file
1, Fig. S1B). Again, subtype AE was less prone to activa-
tion by Vorinostat as compared to the other subtypes.
Compared to subtype B, AE has increased basal tran-
scription levels and shows reduced latency. To ensure
that the measurements were still in the linear range of
the assay, SupT1 cells were infected with different
amounts of subtype AE or B virus. As expected, the
basal percentage of CA-p24 positive cells was always
higher for AE than B (Figure 5A). Likewise, the fold
activation was always higher for B than AE. Additionally,
the TNFa induced activation from latency for subtype
AE remained around 1.5-fold (Figure 5B). These results
demonstrate that subtype AE measurements are within
the linear range of the assay and, more importantly, that
AE is less responsive to TNFa induction since the AE
promoter activity is higher compared to B at basal
settings.
Figure 4 Influence of the HIV-1 promoter on proviral latency. A: Viruses containing the indicated subtype specific LTR promoter were used
in the latency assay. BC: Fold activation from latency with TNFa (B) and Vorinostat (C). The results are the average values that were obtained
with two independently produced virus stocks, each tested in two independent infections. P values * = p < 0.05, ** = p < 0.01, *** = p < 0.001
were determined with the One Way ANOVA (Graphpad Prism).
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To investigate if the obtained results are specific for
SupT1 cells, we repeated the experiments in Jurkat cells
because many HIV-1 latency studies have been per-
formed using this T cell line [17,18,30,38]. The percen-
tage of CA-p24 positive cells without induction,
reflecting the basal transcription level, was slightly
higher for AE as compared to B (1.2 and 1.0% respec-
tively, Additional File 2, Fig. S2A). However, activation
from latency by TNFa induction was significantly higher
for B than for AE (Additional File 2, Fig. S2B). These
results demonstrate that subtype AE also exhibits
reduced latency compared to subtype B in the Jurkat
T cell line.
NFB versus GABP
Infection of T cells with HIV-1 subtype AE yields more
CA-p24 producing cells than equivalent infections with
subtype B. On the other hand, TNFa induced activation
from latency is reduced for AE compared to B, which
thus yield similar end production levels. Arguably, the
AE LTR might be less prone to become silenced due to
the presence of the unique GABP binding site instead of
the regular second NFB site present in the other sub-
types. The GA binding protein (GABP) complex is com-
posed of two subunits. GABPa binds to the DNA and
GABPb contains the transcriptional transactivation
domain. This transcription factor has been demonstrated
to have a role in basic cellular functions and has recently
been described to have a critical role in differentiation
and maintenance of hematopoietic progenitor cells [41].
To investigate if the GABP binding site is responsible for
the increased basal transcription level and decreased
TNFa response, we made several alterations in the two
promoters and tested latency properties (Figure 6A).
Replacing the GABP with a second NFB binding site in
the AE promoter (AE+2xNFB) slightly decreased the
basal transcription level and subsequently increased the
TNFa response (Figure 6BC). Activation from latency
increases significantly from 1.6-fold for AE to 2.3-fold for
AE+2xNFB. To examine if GABP is the sole factor that
is responsible for this effect, we subsequently converted
the upstream NFB into a GABP site in subtype B
(B+GABP). The basal transcription level increased from
2.3 for B to 3.1 for B+GABP, which is not statistically sig-
nificant. However, the GABP insertion altered the TNFa
response which decreased significantly from 2.6-fold for
B to 1.9-fold for B+GABP. Taken together, these results
demonstrate that the NFkB to GABP conversion partially
explains the higher basal activity combined with lower
response to activation but that GABP is probably not the
sole responsible factor.
Discussion
HIV-1 proviral latency is a major barrier towards virus
eradication from the infected patient. This latent virus
reservoir is established early in infection [7,12]. In this
manuscript, we introduce a latency model system that
creates the opportunity to study proviral latency in
actively dividing T cells. The model is based upon a sin-
gle round infection in combination with FACS analysis to
determine virus production per cell. A major advantage
of this model system is the use of wild type HIV-1
instead of plasmids or sub-genomic reporter constructs.
Additionally, the infected cells do not need to be cultured
for an extended period, thus allowing one to study
latency directly after infection in wild type cells without
selection, in contrast to previous described latency model
cell lines such as U1, ACH-2, OM-10.1 and J-Lat [42-45].
In principle, our method can be applied to any type of
cell susceptible to HIV-1 infection.
Figure 5 Latency profile comparison of HIV-1 subtypes AE and B. A: SupT1 T cells were infected with increasing virus concentrations of
subtype B or AE (3, 9, 27 and 81 ng/infection CA-p24) in the presence or absence of TNFa. B: Fold activation with TNFa for subtypes AE and B
with the indicated viral inputs. The results presented reflect the average of three independently produced virus stocks and each stock was used
in two independent infections. The HIV-1 input (ng/infection) was based on CA-p24 ELISA.
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In an acute HIV-1 infection model with the SupT1
T cell line, we demonstrate that a low percentage of the
infected cells is able to express the integrated provirus.
The majority of infected cells carry a latent provirus,
which we could identify upon provirus activation from
latency by TNFa. For HIV-1 subtype B, we measured a
3-fold increase in the percentage of CA-p24 positive
cells. However, the amount of viral CA-p24 production
per producing cell did not increase. The HDAC inhibi-
tor Vorinostat was also able to activate latent provirus,
although less efficient than TNFa. Combinations of
both anti latency drugs did not yield any further signifi-
cant increases in activation.
Culturing the infected cells over an extended period
caused a relative decrease in the number of CA-p24 posi-
tive cells. Transcriptional silencing of active proviruses
seems unlikely because we use actively dividing T cells. It
seems more likely that the decrease in percentage of CA-
p24 positive cells is due to cell death induced by HIV-1
[46]. In addition, as HIV-1 induces cell cycle arrest [47],
virus producing cells can no longer proliferate, and thus
their percentage will gradually decline relative to
uninfected cells. Considering both factors, the decrease
in CA-p24 positive cells seems relatively slow. This might
be due to replenishment of the CA-p24 producing popu-
lation by cells with a latent provirus that becomes tran-
scriptionally active, which is in agreement with the
stochastic model of HIV-1 reactivation [48-50]. We
demonstrate that latent proviruses remain present, as
TNFa was still able to induce a significant increase in the
CA-p24 positive population at day 15. In fact, activation
increased from 3-fold at day 2 to 10-fold at day 15. How-
ever, the absolute percentage of CA-p24 positive cells
obtained upon TNFa treatment decreases over time. The
latter observation further supports the hypothesis of sto-
chastic activation of latently integrated provirus, causing
this population to slowly decline. Alternatively, some of
the latent proviruses may become silenced more strin-
gently over time such that TNFa no longer suffices for
activation. We are currently studying both options.
We have analyzed the promoter of different HIV-1 sub-
types and observed that subtypes A, C, D, F and AG have
similar latency profiles as B. Interestingly, the promoter
of subtype C contains a third consensus DNA sequence
Figure 6 LTR promoter elements of subtypes B and AE. A: The core promoter elements in the LTR of subtypes B and AE. Indicated
transcription factor binding sites are: RBEIII, NFB, GABP, Sp1 and the TATA box. BseA1 indicates the recognition site for the endonuclease used
for molecular cloning. B: Percentages of CA-p24 positive cells without induction determined by FACS. C: Fold activation by TNFa induction. The
results are presented as the average values of three independently produced virus stocks, each tested in two independent infections. P values:
* = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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for NFB binding [51]. Although it has not been shown
that this site is actually bound by NFB, experiments
with LTR-luciferase reporter plasmids have demonstrated
that subtype C promoter activity is increased compared
to subtype B upon stimulation with TNFa or other
NFB activators [22,25,38,52-54]. Viral fitness studies
have also demonstrated relative advantages for the sub-
type C promoter in a TNFa-rich environment [26]. How-
ever, in terms of proviral latency, we did not observe a
significant difference between C and the other subtypes.
Subtype AE clearly exhibits a reduced level of latency,
which correlates with a GABP instead of NFB tran-
scription factor binding site in the LTR. The GABP-to-
NFB mutation in the AE promoter only slightly
reduced the basal transcription level but did restore the
TNFa response. The reciprocal experiment, the NFB-
to-GABP switch in subtype B, did not alter the basal
levels but did significantly reduce the TNFa response.
Thus, the GABP site is an important (but probably not
the sole) determinant of the subtype AE specific proper-
ties. We are currently investigating other sequence var-
iations between subtype AE and B to further elucidate
the observed differences.
Opijnen et al. demonstrated that the LTR impact on
viral replication depends on the cellular environment,
either by host cell type or the presence of activators [26].
Subtype AE out-competed all other subtypes in the
SupT1 T cell line. However, subtype AE became the
worst competitor upon TNFa addition. Our observations
indicate that the AE promoter has an advantage over the
other subtype-specific promoters in a TNFa-poor envir-
onment, in part due to the unique GABP site causing AE
to become latent less frequently than the other subtypes.
Interestingly, a long-term culture of SupT1 T cells
infected with a Tat-defective poorly replicating, HIV-1LAI
variant, resulted in a spontaneous NFB-to-GABP con-
version, which significantly increased viral replication
[55]. This also indicates strong differences between sub-
types AE and B in their replication and latency profiles.
Because subtype AE proviruses are less prone to become
latent, this may translate in higher chances of purging
the reservoir. In other words, a cure may be within closer
reach for subtype AE infected individuals.
Conclusions
We used a novel model of HIV-1 infection to study pro-
viral latency in actively dividing T cells, of which the
majority only support viral gene expression after TNFa
activation. We measured no gross differences among the
HIV-1 subtypes, both in the initial latency property and
the activation response, except for subtype AE that com-
bines an increased level of basal transcription with a
reduced TNFa response. This subtype AE property is
related to the presence of a GABP instead of NFB bind-
ing site in the viral LTR promoter.
Methods
Cells and viruses
HEK 293T cells were grown as a monolayer in Dulbecco’s
minimal essential medium supplemented with 10% (v/v)
fetal calf serum (FCS), 40 U/ml penicillin, 40 μg/ml strep-
tomycin, 20 mM glucose and minimal essential medium
nonessential amino acids at 37°C and 5% CO2. The
human T lymphocytic cell lines SupT1 (ATCC CRL-1942)
[56] and Jurkat (ATCC TIB-152) were cultured in
advanced RPMI 1640 medium (Gibco BRL, Gaithersburg,
MD) supplemented with 1% (v/v) FCS, 40 U/ml penicillin,
and 40 μg/ml streptomycin at 37°C and 5% CO2. HIV-1
infections were performed with 293T produced virus
stocks of the different HIV-1 molecular clones. The cells
were transfected with plasmid DNA of the HIV-1 LAI
molecular clone [57] or derivates thereof by the calcium
phosphate method as described previously [58]. LTRs
from patient isolates representing subtype A, C, D, AE
(CRF_01), F, G and AG (CRF_02) were selected as being
representative of the viral quasi species in the patient and
the HIV-1 subtypes [22]. These subtype-specific LTRs
were cloned into the common viral backbone of HIV-1LAI
(subtype B). The recombinant viruses are isogenic except
for the core promoter region containing the major TFBS,
thus preventing differences in fusion, integration etc. The
variable LTR region spans only 150 bp, containing the
major TFBS, but still encoding a subtype B TAR hairpin.
The concentration of the produced virus stocks was deter-
mined by CA-p24 ELISA.
Reagents
TNFa (Invitrogen PHC3015) was prepared in sterile
milliQ H2O (stock solution 10 μg/ml) and used at a
final concentration of 50 ng/ml. Fusion inhibitor
T1249 (WQEWEQKITALLEQAQIQQEKNEYELQKL
DKWASLWEWF, Pepscan Therapeutics BV, Lelystad,
the Netherlands) was obtained as a 10.000 × stock
solution of 1 mg/ml. Vorinostat was donated by Frank
Dekker (Groningen University, the Netherlands). The
lyophilized powder was dissolved in DMSO (2 mM
stock solution) and used at a final concentration of
0.3 μM.
HIV-1 latency assay
Single round infection assay
SupT1 or Jurkat T cells (0.5 × 106 cells) were infected
with virus stocks of the primary CXCR4-using LAI isolate
or derivatives containing a subtype-specific 3’LTR. Excess
virus was washed away after four hours and the cells
were cultured in the presence of the fusion inhibitor
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T1249 to block all subsequent viral entry. The cultures
were split 24 hours post-infection, and TNFa was added
to a single culture. After another 24 hours, we measured
intracellular CA-p24 by FACS analysis and extracellular
CA-p24 production in the culture medium by ELISA. To
equalize infections, input CA-p24 was kept similar
among subtype-specific infections and conditional med-
ium was added to reach a 200 μl infection volume.
Intracellular CA-p24 staining and fluorescence-activated cell
sorting
Flow cytometry was performed with RD1- or FITC-con-
jugated mouse monoclonal anti-CA-p24 (clone KC57,
Coulter). Cells were fixed in 4% formaldehyde for at
least 5 min at room temperature, washed with FACS
buffer (PBS with 10% FCS) and kept at 4°C. The cells
were washed with BD Perm/Wash™ buffer (BD Phar-
mingen) and stained for at least 30 minutes at 4°C with
the appropriate antibody diluted 1:100 in BD Perm/
Wash™ buffer. Excess antibody was removed by wash-
ing the cells with BD Perm/Wash™ buffer and the cells
were resuspended in FACS buffer. Cells were analyzed
on a BD FACSCanto II flow cytometer with BD FACS-
Diva Software v6.1.2 (BD biosciences, San Jose, CA).
Cell populations were defined based on forward/side-
ward scattering. Results from different assays were cor-
rected for between-session variation with the factor
correction program [59].
Extracellular CA-p24 ELISA
Culture supernatant was heat inactivated at 56°C for 30
minutes in the presence of 0.05% Empigen-BB (Calbio-
chem, La Jolla, USA). The CA-p24 concentration was
determined by a twin-site ELISA with D7320 (Biochrom,
Berlin, Germany) as capture antibody and alkaline phos-
phatase-conjugated anti-p24 monoclonal antibody (EH12-
AP) as detection antibody. Quantification was performed
with the lumiphos plus system (Lumigen, Michigan, USA)
in a LUMIstar Galaxy (BMG labtechnologies, Offenburg,
Germany) luminescence reader. Recombinant CA-p24
produced in a baculovirus system was used as a standard.
Plasmids
Cloning of the different subtype specific LTRs (A, C1. C2,
D, AE = CRF01, F, G and AG = CRF02) into the full
length LAI molecular clone has been described previously
[22]. Subtype C1 and C2 do not refer to the different C
subclusters, C and C’, but resemble two variants within
subcluster C [60,61]. Introduction of the GABP instead of
the upstream NFB site in the promoter of subtype B has
previously been described [55]. An additional construct
was made converting the unique GABP site in the subtype
AE LTR into a second NFB site. Plasmid pBlue3’LTR AE
[22] was used as template in two independent PCR reac-
tions under standard conditions. PCR primers 5’ TAG
GGA CTT TCC GCT GGG GAC TTT CC3’ and 5’TGT
CTC ATG AGC GGA TAC ATA3’ were used in reaction
A (italics indicate the NFB-II site). Reaction B was per-
formed with primers 5’GTC CCC TGC GGA AAG TCC
CTA GTT AG3’ and 5’TGG AAG GGC TAA TTC ACT
CCC3’. Both PCR products, purified from gel, were used
as templates in a third PCR under standard conditions
with primers 5’TGT CTC ATG AGC GGA TAC ATA3’
and 5’TGG AAG GGC TAA TTC ACT CCC3’. The 833
bp PCR product was digested with BseA1 and HindIII,
purified and ligated into pBlue3’LTR. The mutated sub-
type AE LTR was cloned from pBlue3’LTR into pLAI [57]
using the XhoI and BglI restriction sites and verified by
sequencing.
Quantitative TaqMan assay
TaqMan assays were used to quantify the number of
HIV-1 DNA copies in infected cultures. In brief, cells
were resuspended in Tris-EDTA (10 mM pH 8.3) con-
taining 0.5 units/μl proteinase K (Roche Applied
Science), incubated for 1 hour at 56°C and 10 min at
95°C and directly used for PCR amplification. The num-
ber of input cells was determined using TaqMan®
reagents for quantification of b-actin DNA (AB, Applied
Biosystems) according to the manufacturer’s instruction.
HIV-1 DNA was detected with a semi-nested real-time
PCR assay with a pre-amplification step that is exclusive
for completely reverse transcribed HIV-1 DNA. The
pre-amplified product was subsequently quantified by
real-time PCR as previously described [62].
Additional material
Additional File 1: Figure S1 HIV-1 activation from proviral latency
over time. SupT1 T cells were infected with the different subtypes. On
day 2, 7 and 14 the cells were induced with TNFa (A), Vorinostat (B),
mock treated or passaged and cultured for another week, followed by a
repeat of the protocol. The cells were harvested 24 hours after treatment
(day 3, 8 and 15, respectively) and analyzed by FACS for CA-p24
positivity. The fold activation from latency increases over time for all the
subtypes except AE.
Additional File 2: Figure S2 Latency in the Jurkat T cell line. Jurkat
cells were infected with subtype B or AE in the format of the latency
assay. A: Percentage of CA-p24 positive cells without inducer. B: The
TNFa induced fold activation from latency. The results are presented as
the average values of three independently produced virus stocks of
which each stock is used for two independent infections. P values: *** =
p < 0.001.
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